{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T05:15:19Z","timestamp":1716614119851},"reference-count":18,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2022,9,30]]},"DOI":"10.7883\/yoken.jjid.2021.699","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:10:30Z","timestamp":1651097430000},"page":"484-489","source":"Crossref","is-referenced-by-count":4,"title":["Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study"],"prefix":"10.7883","volume":"75","author":[{"given":"Tomomi","family":"Soma","sequence":"first","affiliation":[{"name":"Department of Nephrology, Japan Community Health care Organization Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Saiseikai Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Saiseikai Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketomo","family":"Maruki","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tokyo Saiseikai Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Taniyama","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Showa General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, National Hospital Organization Kanagawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.","DOI":"10.1001\/jama.2020.2648"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-793.","DOI":"10.1001\/jama.2020.12839"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Horby P, Lim WS, Emberson JR, et al. ; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491-1502.","DOI":"10.1056\/NEJMoa2100433"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19\u2015final report. N Engl J Med. 2020;383:1813-1826.","DOI":"10.1056\/NEJMc2022236"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12:629.","DOI":"10.3390\/v12060629"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Doi K, Ikeda M, Hayase N, et al. ; COVID-UTH Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020; 24:392.","DOI":"10.1186\/s13054-020-03078-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hofmann-Winkler H, Moerer O, Alt-Epping S, et al. Camostat mesylate may reduce severity of coronavirus disease 2019 sepsis: a first observation. Crit Care Explor. 2020;2:e0284.","DOI":"10.1097\/CCE.0000000000000284"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382-1392.","DOI":"10.1056\/NEJMoa2102685"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-1099.","DOI":"10.1111\/jth.14817"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020;18:1521-1522.","DOI":"10.1111\/jth.14858"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67.","DOI":"10.1007\/s11239-020-02134-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamamoto M, Matsuyama S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60:6532-6539.","DOI":"10.1128\/AAC.01043-16"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64:e00754-20.","DOI":"10.1128\/AAC.00754-20"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Okajima M, Takahashi Y, Kaji T, et al. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports. World J Clin Cases. 2020;8:5320-5325.","DOI":"10.12998\/wjcc.v8.i21.5320"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol. 1995;26:1627-1632.","DOI":"10.1016\/0306-3623(95)00072-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Abdulgabbar MH. Clinical efficacy of nafamostat mesylate in combination with favipiravir for COVID-19 pneumonia treatment review article. Ann Med Surg. 2021;68:102560.","DOI":"10.1016\/j.amsu.2021.102560"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/5\/75_JJID.2021.699\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T04:52:20Z","timestamp":1663995140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/5\/75_JJID.2021.699\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2021.699","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"JJID.2021.699"}}